Physician profile
Amy Lorraine Sobas
NPI 1205872132
$4,700.93
in general payments reported to CMS, 2019-2025
38 companies · $817 in 2025
The $817 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $932 · 2022: $1,033 · 2023: $977 · 2024: $942 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $958.16 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $610.62 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $564.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $529.09 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $293.23 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $252.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.88 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $148.36 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.48 | 2021-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $95.22 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $93.13 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $83.63 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $83.22 | 2021 | |
| Corium, LLC | $78.94 | 2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $73.07 | 2021-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Sobas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.